{"entity":{"id":"da-trial-trontier","kind":"trial","name":"TRONTIER 2 (trontinemab Phase 3)","aka":[],"tldr":"TRONTIER 2 is a Phase 3 study of trontinemab in early symptomatic Alzheimer’s disease. Confirm eligibility only via ClinicalTrials.gov and a clinician.","summary":"Roche’s Brainshuttle anti-amyloid Phase 3 programme. A registry listing is not a recommendation to join a study.","status":"recruiting","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT07170150","url":"https://clinicaltrials.gov/study/NCT07170150"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease","mild-cognitive-impairment"],"sections":[],"technologies":[],"targets":[],"drugs":["da-trontinemab"],"companies":["da-roche"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07170150","phase":"3","setting":"Early Alzheimer’s disease","sponsor":"Roche","outcomes":[]},"route":"/trials/da-trial-trontier/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"},{"id":"mild-cognitive-impairment","kind":"cancer","name":"Mild cognitive impairment","route":"/diagnoses/mild-cognitive-impairment/"}],"drug":[{"id":"da-trontinemab","kind":"drug","name":"Trontinemab","route":"/drugs/da-trontinemab/"}],"company":[{"id":"da-roche","kind":"company","name":"Roche","route":"/companies/da-roche/"}]}}